posted on 2023-12-06, 06:06authored byJayalakshmi Jayan, Jiseong Lee, Sunil Kumar, Amritha Manoharan, Anishma Payyappilliparambil Narayanan, Reenoo Jauhari, Mohamed A. Abdelgawad, Mohammed M. Ghoneim, Hasnaa Ali Ebrahim, Subin Mary Zachariah, Hoon Kim, Bijo Mathew
A total of 14 acyl hydrazine derivatives (ACH1–ACH14) were developed and examined for their ability to block monoamine
oxidase (MAO). Thirteen analogues showed stronger inhibition potency
against MAO-B than MAO-A. With a half-maximum inhibitory concentration
of 0.14 μM, ACH10 demonstrated the strongest inhibitory
activity against MAO-B, followed by ACH14, ACH13, ACH8, and ACH3 (IC50 = 0.15,
0.18, 0.20, and 0.22 μM, respectively). Structure–activity
relationships suggested that the inhibition effect on MAO-B resulted
from the combination of halogen substituents of the A- and/or B-rings.
This series concluded that when –F was substituted to the B-ring,
MAO-B inhibitory activities were high, except for ACH6. In the inhibition kinetics study, the compounds ACH10 and ACH14 were identified as competitive inhibitors,
with Ki values of 0.097 ± 0.0021
and 0.10 ± 0.038 μM, respectively. In a reversibility experiment
using the dialysis methods, ACH10 and ACH14 showed effective recoveries of MAO-B inhibition as much as lazabemide,
a reversible reference. These experiments proposed that ACH10 and ACH14 were efficient, reversible competitive MAO-B
inhibitors. In addition, the lead molecules showed good blood–brain
barrier permeation with the PAMPA method. The molecular docking and
molecular dynamics simulation study confirmed that the hit compound
ACH10 can form a stable protein–ligand complex by forming a
hydrogen bond with the NH atom in the hydrazide group of the compound.